Rich Horgan believes that there's an alternative path to drug development that can lower costs and the time it takes to bring drugs to market. He is trying to apply it to the field of rare and ultra-rare diseases.
The founder and CEO of Unlearn.AI seeks to make clinical trials more efficient and less costly by leveraging its Digital Twin technology. If the company is successful, drugs could potentially be brought to market sooner and in a cost effective manner.
I interview Punit Singh Soni, CEO of Suki and Niall O'Connor, CTO, Cohere Health to evaluate two areas where AI can have an outsize impact: clinical documentation and prior authorization.
A conversation with Suchi Saria, associate professor of medicine at John Hopkins University and director of its Machine Learning and Healthcare Lab about responsible AI.